drugset
drugset / Trial / NCT03465709

Pegcetacoplan (APL-2) in Neovascular AMD

NCT03465709 ↗

Phase 1/2 Terminated 17 enrolled Apellis Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD

Timeline

Start
2018-02-14
Primary completion
2019-04-05
Completion
2019-04-05

Outcome

Outcome not reported

Stopped: “Apellis concluded that sufficient data were collected to meet the study objectives.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegcetacoplan Peptide — Intravitreal

Indications

wet macular degeneration